Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics.
Xenia Marlene HartGerhard GründerNicolas AnsermotAndreas ConcaEmmanuelle CorrubleSeverine CrettolPaul CummingGudrun HefnerAriel FrajermanOliver D HowesMarin M JukićEuitae KimSeoyoung KimIgnazio ManiscalcoSho MoriguchiDaniel J MuellerShinichiro NakajimaMartin OsugoMichael PaulzenHenricus Gerardus RuheMaike Scherf-ClavelGeorgios SchoretsanitisAlessandro SerrettiEdoardo SpinaOlav SpigsetWerner SteimerSinan H SüzenHiroyuki UchidaStefan UntereckerFrederik VandenbergheCéline VerstuyftGerald ZernigChristoph HiemkeChin Bin EapPublished in: The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry (2024)
All three tools discussed in these Guidelines are essential for drug treatment. TDM goes well beyond typical indications such as unclear compliance and polypharmacy. Despite its enormous potential to optimise treatment effects, minimise side effects and ultimately reduce the global burden of diseases, personalised drug treatment has not yet become the standard of care in psychiatry.